Urology: Upper-tract urothelial adjuvant chemotherapy
Free question published 14 September 2026
A 67-year-old man undergoes radical nephroureterectomy for upper-tract urothelial carcinoma. Final histology is pT3 N0, high grade, margins clear. His postoperative estimated glomerular filtration rate is 58 mL/min and his performance status is 0. He is reviewed in clinic 5 weeks after surgery. What is the most appropriate adjuvant management?
- AAdjuvant radiotherapy directed to the renal bed surgical resection site
- BAdjuvant intravesical BCG
- CAdjuvant gemcitabine-platinum combination chemotherapy
- DAdjuvant single-agent pembrolizumab
- ESurveillance with no adjuvant therapy
Why C is correct
The POUT trial showed that adjuvant gemcitabine-platinum chemotherapy started within 90 days of nephroureterectomy significantly improved disease-free survival in locally advanced (pT2 to pT4 or node-positive) upper-tract urothelial carcinoma (HR 0.45). With an eGFR of 58 mL/min he is cisplatin-eligible, and the authors concluded adjuvant platinum-based chemotherapy should be considered a new standard of care.
And why the others are not
- AIncorrect: adjuvant renal-bed radiotherapy is not the POUT-supported standard for this setting.
- BIncorrect: intravesical BCG treats non-muscle-invasive bladder disease, not the adjuvant management of resected upper-tract urothelial carcinoma.
- DIncorrect: POUT established platinum-based chemotherapy, not single-agent adjuvant immunotherapy, as standard of care here.
- EIncorrect: surveillance alone yielded inferior disease-free survival (3-year 46% vs 71%) in POUT.
Source POUT — Adjuvant chemotherapy in upper-tract urothelial carcinoma — Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet 2020;395(10232):1268-1277.
More free urology questions
- Urology: Muscle-invasive bladder neoadjuvant chemotherapy · 03 September 2026
- Urology: Muscle-invasive bladder bladder-preservation chemoRT · 23 August 2026
- Urology: Low-risk prostate active surveillance · 12 August 2026
Sitting in February? Follow the twenty-week plan.
2,500+ cited questions like this one are waiting in the vault.
See plans and pricing